词条 | Tumor marker | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
释义 |
A tumor marker is a biomarker found in blood, urine, or body tissues that can be elevated by the presence of one or more types of cancer. There are many different tumor markers, each indicative of a particular disease process, and they are used in oncology to help detect the presence of cancer. An elevated level of a tumor marker can indicate cancer; however, there can also be other causes of the elevation (false positive values). Tumor markers can be produced directly by the tumor or by non-tumor cells as a response to the presence of a tumor. Although mammography, ultrasonography, computed tomography, magnetic resonance imaging scans, and tumor marker assays help in the staging and treatment of the cancer, they are usually not definitive diagnostic tests. The diagnosis is mostly confirmed by biopsy.[1] ClassificationOn the basis of their chemical nature tumor markers can be proteins, conjugated proteins, peptides and carbohydrates. Proteins or conjugated proteins may be enzymes, hormones or fragments of proteins. Sequencing of genes for diagnostic purposes is mostly classified under the biomarker heading and is not discussed here. UsesTumor markers may be used for the following purposes:
As stated in the BMJ 2009, tumor markers should not generally be used for the purpose of diagnosis of cancers, as opposed to monitoring purposes in certain cancers, or in certain cases, for screening purposes.[2] The use of these tests without understanding their utility has resulted in inappropriate use of tumor marker blood tests, which has resulted in inappropriate over-investigation for cancers.[3] TechniquesTumor markers can be determined in serum or rarely in urine or other body fluids, often by immunoassay but other techniques such as enzyme activity determination are sometimes used. Microscopic visualization in tissue by immunohistochemistry does not give quantitative results and is not considered here. For many assays, different assay techniques are available. For monitoring it is important that the same assay is used as the results from different assays are generally not comparable. For example, for AFP many different commercial assay kits, based on different technologies, are available and for thymidine kinase there are assays for either enzyme activity or amount of substance. If repeated measurements of tumor marker are needed, some clinical testing laboratories provide a special reporting mechanism, a serial monitor that links test results and other data pertaining to the person being tested. This requires a unique identifier for the person. In the United States commonly a Social Security number & Civil Personal Record (CPR) in Bahrain are used for this. Interlaboratory proficiency testing for tumor marker tests, and for clinical tests more generally, is routine in Europe and an emerging field.[4] in the United States. New York state is prominent in advocating such research.[5] List of commonly used markers
Precision and accuracyThe required precision and accuracy for different analytes varies: some analytes give small or moderate changes in concentration or activity, thereby requiring high accuracy and precision to be useful while others that show large differences between normal and pathological values may be useful even if the precision and accuracy are inferior. Therefore, the required precision and accuracy for a given assay may be different for different applications such as in different diagnoses or for different uses. This also influences the useful working range for a given assay for different diagnosis or uses. Every laboratory should verify the precision and accuracy of the assays with the instruments and personnel used. The high dose hook effect is an artifact of immunoassay kits, that causes the reported quantity to be incorrectly low when the quantity is high. An undetected hook effect may cause delayed recognition of a tumor.[25] The hook effect can be detected by analyzing serial dilutions. The hook effect is absent if the reported quantities of tumor marker in a serial dilution are proportional to the dilution. Multiple Tumor marker testAs with other diagnostic tests, tumor markers have a few test characteristics that influence their usability:
As with other tests, predictive value (the chance that a positive or negative result represents the truth), depends strongly on the pre-test probability. The predictive value may be increased if two or more tests are carried out in parallel. The condition is that the tests have in themselves similar predictive values. Test combinations that will give more exact results are for instance:[1]
See also
References1. ^1 {{cite web |url=http://www.cancersafe.com/screening/index.asp |title=Tumor markers Cancer screening |accessdate=December 28, 2013}} 2. ^{{cite journal |doi=10.1136/bmj.b3111 |title=Appropriate requesting of serum tumour markers |year=2009 |last1=Kilpatrick |first1=E. S |last2=Lind |first2=M. J |journal=BMJ |volume=339 |pages=b3111 |pmid=19773324}} 3. ^{{cite journal |doi=10.1136/bmj.325.7370.946 |title=Lesson of the week: Hypothyroidism mimicking intra-abdominal malignancy |year=2002 |last1=Krishnan |first1=S T M |journal=BMJ |volume=325 |issue=7370 |pages=946–7 |pmid=12399347 |last2=Philipose |first2=Z |last3=Rayman |first3=G |pmc=1124444}} 4. ^{{cite journal |doi=10.1002/1097-0142(19920315)69:6+<1578::AID-CNCR2820691312>3.0.CO;2-K |title=Molecular marker test standardization |year=1992 |last1=Koepke |first1=John A. |journal=Cancer |volume=69 |pages=1578–81 |pmid=1540898 |issue=6 Suppl}} 5. ^Promoting Safe and Effective Genetic Testing in the United States genome.gov 6. ^1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 [https://books.google.com/books?id=pobC8zHbWzwC&pg=PA746 Page 746] in: Title Manual of clinical oncologySpiral manualManual of Clinical OncologyLippincott Manual SeriesAuthors Dennis Albert Casciato, Mary C. TerritoEditors Dennis Albert Casciato, Mary C. TerritoContributor Mary C. TerritoEdition 6, illustratedPublisher Lippincott Williams & Wilkins, 2008{{ISBN|0-7817-6884-5}}, {{ISBN|978-0-7817-6884-9}} 7. ^{{cite journal |doi=10.1093/annonc/mdl492 |title=CA15-3 and alkaline phosphatase as predictors for breast cancer recurrence: A combined analysis of seven International Breast Cancer Study Group trials |year=2006 |last1=Keshaviah |first1=A |last2=Dellapasqua |first2=S |last3=Rotmensz |first3=N |last4=Lindtner |first4=J |last5=Crivellari |first5=D |last6=Collins |first6=J |last7=Colleoni |first7=M |last8=Thurlimann |first8=B |last9=Mendiola |first9=C |last10=Aebi |first10=S |last11=Price |first11=K. |last12=Pagani |first12=O |last13=Simoncini |first13=E |last14=Castiglione Gertsch |first14=M |last15=Gelber |first15=R. |last16=Coates |first16=A. |last17=Goldhirsch |first17=A |journal=Annals of Oncology |volume=18 |issue=4 |pages=701–8 |pmid=17237474|display-authors=8 }} 8. ^{{cite web |title=Definition of CA 27-29. From MedicineNet. Last Editorial Review: 6/14/2012 |url=http://www.medterms.com/script/main/art.asp?articlekey=39199}} 9. ^[https://gpnotebook.co.uk/simplepage.cfm?ID=-80412627 gpnotebook.co.uk > ca-19-9] Retrieved November 2011 10. ^{{cite journal |vauthors=Osman N, O'Leary N, Mulcahy E, Barrett N, Wallis F, Hickey K, Gupta R | title = Correlation of serum CA125 with stage, grade and survival of patients with epithelial ovarian cancer at a single centre | journal = Ir Med J | volume = 101 | issue = 8 | pages = 245–7 |date=September 2008 | pmid = 18990955 | doi = | url = | issn = }} 11. ^{{cite journal |vauthors=Bast RC, Xu FJ, Yu YH, Barnhill S, Zhang Z, Mills GB | title = CA 125: the past and the future | journal = Int. J. Biol. Markers | volume = 13 | issue = 4 | pages = 179–87 | year = 1998 | pmid = 10228898 | doi = | url = | issn = }} 12. ^{{cite journal |vauthors=Bagan P, Berna P, Assouad J, Hupertan V, Le Pimpec Barthes F, Riquet M | title = Value of cancer antigen 125 for diagnosis of pleural endometriosis in females with recurrent pneumothorax | journal = Eur. Respir. J. | volume = 31 | issue = 1 | pages = 140–2 |date=January 2008 | pmid = 17804443 | doi = 10.1183/09031936.00094206 | url = }} 13. ^{{cite web |url=http://www.cancer.gov/cancertopics/factsheet/detection/tumor-markers |title=Tumor Markers |accessdate=June 6, 2013}} 14. ^{{cite journal |doi=10.1038/sj.bjc.6603712 |title=Tumour M2-PK as a stool marker for colorectal cancer: Comparative analysis in a large sample of unselected older adults vs colorectal cancer patients |year=2007 |last1=Haug |first1=U |last2=Rothenbacher |first2=D |last3=Wente |first3=M N |last4=Seiler |first4=C M |last5=Stegmaier |first5=C |last6=Brenner |first6=H |journal=British Journal of Cancer |pmid=17406361 |pmc=2360192 |volume=96 |issue=9 |pages=1329–34}} 15. ^{{cite journal |pmid=11326672 |year=2000 |last1=Lüftner |first1=D |last2=Mesterharm |first2=J |last3=Akrivakis |first3=C |last4=Geppert |first4=R |last5=Petrides |first5=PE |last6=Wernecke |first6=KD |last7=Possinger |first7=K |title=Tumor type M2 pyruvate kinase expression in advanced breast cancer |volume=20 |issue=6D |pages=5077–82 |journal=Anticancer Research}} 16. ^{{cite journal |pmid=20592362 |year=2010 |last1=Benesch |first1=C |last2=Schneider |first2=C |last3=Voelker |first3=HU |last4=Kapp |first4=M |last5=Caffier |first5=H |last6=Krockenberger |first6=M |last7=Dietl |first7=J |last8=Kammerer |first8=U |last9=Schmidt |first9=M |title=The clinicopathological and prognostic relevance of pyruvate kinase M2 and pAkt expression in breast cancer |volume=30 |issue=5 |pages=1689–94 |journal=Anticancer Research }} 17. ^{{cite journal |pmid=11326675 |year=2000 |last1=Oremek |first1=GM |last2=Sapoutzis |first2=N |last3=Kramer |first3=W |last4=Bickeböller |first4=R |last5=Jonas |first5=D |title=Value of tumor M2 (Tu M2-PK) in patients with renal carcinoma |volume=20 |issue=6D |pages=5095–8 |journal=Anticancer Research}} 18. ^{{cite journal |pmid=10470199 |year=1999 |last1=Wechsel |first1=HW |last2=Petri |first2=E |last3=Bichler |first3=KH |last4=Feil |first4=G |title=Marker for renal cell carcinoma (RCC): The dimeric form of pyruvate kinase type M2 (Tu M2-PK) |volume=19 |issue=4A |pages=2583–90 |journal=Anticancer Research}} 19. ^{{cite journal |pmid=12624710 |year=2003 |last1=Schneider |first1=J |last2=Peltri |first2=G |last3=Bitterlich |first3=N |last4=Philipp |first4=M |last5=Velcovsky |first5=HG |last6=Morr |first6=H |last7=Katz |first7=N |last8=Eigenbrodt |first8=E |title=Fuzzy logic-based tumor marker profiles improved sensitivity of the detection of progression in small-cell lung cancer patients |volume=2 |issue=4 |pages=185–91 |doi=10.1007/s102380300005 |journal=Clinical and Experimental Medicine}} 20. ^{{cite journal |pmid=17882813 |year=2007 |last1=Oremek |first1=G |last2=Kukshaĭte |first2=R |last3=Sapoutzis |first3=N |last4=Ziolkovski |first4=P |title=The significance of TU M2-PK tumor marker for lung cancer diagnostics |volume=85 |issue=7 |pages=56–8 |journal=Klinicheskaia Meditsina}} 21. ^{{cite journal |pmid=11326648 |year=2000 |last1=Hardt |first1=PD |last2=Ngoumou |first2=BK |last3=Rupp |first3=J |last4=Schnell-Kretschmer |first4=H |last5=Kloer |first5=HU |title=Tumor M2-pyruvate kinase: A promising tumor marker in the diagnosis of gastro-intestinal cancer |volume=20 |issue=6D |pages=4965–8 |journal=Anticancer Research}} 22. ^1 {{cite journal |doi=10.1097/MEG.0b013e3280102f78 |pmid=17301655 |title=Tumour M2-pyruvate kinase: A gastrointestinal cancer marker |year=2007 |last1=Kumar |first1=Yogesh |last2=Tapuria |first2=Niteen |last3=Kirmani |first3=Naveed |last4=Davidson |first4=Brian R. |journal=European Journal of Gastroenterology & Hepatology |volume=19 |issue=3 |pages=265–276}} 23. ^{{cite journal |pmid=15210041 |year=2004 |last1=Kaura |first1=B |last2=Bagga |first2=R |last3=Patel |first3=FD |title=Evaluation of the Pyruvate Kinase isoenzyme tumor (Tu M2-PK) as a tumor marker for cervical carcinoma |volume=30 |issue=3 |pages=193–6 |doi=10.1111/j.1447-0756.2004.00187.x |journal=The Journal of Obstetrics and Gynaecology Research}} 24. ^{{cite journal |pmid=17479666 |year=2007 |last1=Ahmed |first1=AS |last2=Dew |first2=T |last3=Lawton |first3=FG |last4=Papadopoulos |first4=AJ |last5=Devaja |first5=O |last6=Raju |first6=KS |last7=Sherwood |first7=RA |title=M2-PK as a novel marker in ovarian cancer. A prospective cohort study |volume=28 |issue=2 |pages=83–8 |journal=European Journal of Gynaecological Oncology}} 25. ^{{cite journal | vauthors = Leboeuf R, Langlois MF, Martin M, Ahnadi CE, Fink GD | title = "Hook effect" in calcitonin immunoradiometric assay in patients with metastatic medullary thyroid carcinoma: case report and review of the literature | journal = J. Clin. Endocrinol. Metab. | volume = 91 | issue = 2 | pages = 361–4 | date = February 2006 | pmid = 16278263 | doi = 10.1210/jc.2005-1429 }} 26. ^{{cite journal | vauthors = Pastor A, Menéndez R, Cremades MJ, Pastor V, Llopis R, Aznar J | title = Diagnostic value of SCC, CEA and CYFRA 21.1 in lung cancer: a Bayesian analysis | journal = Eur. Respir. J. | volume = 10 | issue = 3 | pages = 603–9 | date = March 1997 | pmid = 9072992}} Further reading
External links
2 : Tumor markers|Biomarkers |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
随便看 |
|
开放百科全书收录14589846条英语、德语、日语等多语种百科知识,基本涵盖了大多数领域的百科知识,是一部内容自由、开放的电子版国际百科全书。